Published Next-Gen Blood Test Predicts Diabetic Kidney Disease Years Before Symptoms

Embargoed until: Publicly released: 2025-07-24 18:00

Australia

Proteomics International has validated its next-generation PromarkerD test in a peer-reviewed study, confirming its ability to predict kidney function decline in adults with type 2 diabetes up to four years in advance. The simple blood test combines protein biomarkers with clinical data to outperform current standard-of-care methods. With exceptional predictive performance and negative predictive value, PromarkerD enables earlier intervention, personalised care, and better resource allocation - helping reduce kidney failure rates. The test is now available in both Australia and the USA.

Multimedia

PromarkerD in the lab

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Oxford University Press, Web page Publication: Analytical and Clinical Performance of a Novel Immunoassay-Based Test System to Predict Diabetic Kidney Disease

Journal/
conference: Journal of Applied Laboratory Medicine

Research:Paper

Organisation/s: Proteomics International Laboratories Ltd

Funder: Partial funding for the proteomics analysis was provided by the Federal Government of Australia under a Commercialization Australia Grant (CAU05922). FDS2 has been supported by the National Health and Medical Research Council of Australia project grants 513781 and 1042231. T.M.E. Davis was supported by a National Health and Medical Research Council of Australia Practitioner Fellowship (1058260). Analysis was performed in the Western Australian (WA) Proteomics Facility, a node of Proteomics Australia and is supported by infrastructure funding from the Western Australian State Government in partnership with Bioplatforms Australia under the Commonwealth Government National Collaborative Research Infrastructure Strategy.

Media Contact/s

Contact details are only visible to registered journalists.